Barrett & Company’s Biogen BIIB Stock Holding History

Barrett & Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.48K	Hold	30	–	–	﹤0.01%	524
2026 Q1	$5.5K	Hold	30	–	–	﹤0.01%	512
2025 Q4	$5.28K	Hold	30	–	–	﹤0.01%	523
2025 Q3	$4.2K	Hold	30	–	–	﹤0.01%	538
2025 Q2	$3.77K	Hold	30	–	–	﹤0.01%	552
2025 Q1	$4.11K	Hold	30	–	–	﹤0.01%	512
2024 Q4	$4.59K	Hold	30	–	–	﹤0.01%	499
2024 Q3	$5.82K	Hold	30	–	–	﹤0.01%	471
2024 Q2	$6.96K	Hold	30	–	–	﹤0.01%	460
2024 Q1	$6.47K	Hold	30	–	–	﹤0.01%	471
2023 Q4	$7.76K	Hold	30	–	–	﹤0.01%	430
2023 Q3	$7.71K	Hold	30	–	–	﹤0.01%	438
2023 Q2	$8.55K	Hold	30	–	–	0.01%	424
2023 Q1	$8.34K	Hold	30	–	–	0.01%	400
2022 Q4	$8.31K	Hold	30	–	–	0.01%	397
2022 Q3	$8.31K	Buy	+30	New	+$6.37K	0.01%	397

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barrett & Company's BIIB Position: Q2 2026 in Review

Barrett & Company held its Biogen (BIIB) position steady in Q2 2026 at 30 shares worth $6.48K. The position accounts for ﹤0.01% of the portfolio, ranked #524.

Barrett & Company first reported a position in BIIB in Q3 2022 and has held it in 16 quarters since. The position peaked at $8.55K in Q2 2023. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Barrett & Company held 30 shares of Biogen worth $6.48K as of Q2 2026.
Barrett & Company left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Barrett & Company's portfolio in Q2 2026, its #524 holding.
Barrett & Company first reported a position in Biogen in Q3 2022 and has held it in 16 quarters since.
Barrett & Company's Biogen position peaked at $8.55K in Q2 2023.
1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.